Alpha-synuclein (α-syn) aggregation is a neuropathological hallmark of many neurodegenerative diseases, collectively
termed synucleinopathies. There is currently no pre-mortem diagnosis tool for these diseases. Although some
compounds have been described as potential ligands for α-syn aggregates, no specific PET radiotracer of aggregated α-syn
is currently available. Recently, [18F]BF227 has been proposed as an α-syn PET radiotracer in the absence of other specific
candidates. We proposed here, for the first time, to use this radiotracer in an accelerated mouse model of synucleinopathy
presenting α-syn depositions in brainstem and thalamus. Our in vivo and in vitro studies showed that [18F]BF227
does not bind to α-syn aggregates. These results highlight the fact that [18F]BF227 PET has no suitable characteristics for
monitoring this experimental synucleinopathy, justifying the need to develop alternative α-syn PET radiotracers.